Comparative Analysis of the Quality of Life Scales Parameters in Patients with Combination of Stable Ischemic Heart Disease and Metabolic Syndrome
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Modern epidemiological studies confirm that comorbid diseases and conditions can have significant impact on diagnostic and treatment of the underlying disease. The problem of the comorbidy of stable coronary heart disease (SCHD) and metabolic syndrome (MS) has high medical and social significance, need high costs for diagnosis and treatment, and leads to decreased of quality of life (QOL). QOL is an important indicator of the health status of patients, which comprehensively characterizes human physical, psychological, emotional and social functioning.
The objective: to conduct a comparative analysis of the QOL of patients with combination of SCAD and MS versus patients with isolated SCHD.
Materials and methods. The study included 102 patients: 52 people with MS in combination with SCAD and 50 patients with SCHD only. There were 42 (51.2%) men (mean age 49.8 ± 5.3 years), and 40 (48.8%) women (mean age 51.6 ± 6.7 years). The QoL score was assessed by general medical questionnaire – the Medical Outcomes Study 36-Item (SF-36), in which all scales form two indicators: mental and physical health and a specialized questionnaire for patient with stable angina pectoris – SAQ (Seattle Angina Questionnaire). The diagnosis of SCHD with functional class (FC) assessment was performed by European Society of Cardiology criteria. MS was established if three out of five diagnostic criteria were met.
Results. Patients with comorbid MS and SCHD demonstrated significantly lower QoL scores, both in psychological and physical components of health (according to the SF-36 questionnaire) compared to patients with SCHD alone (p <0.05). An analysis of the SAQ questionnaire data also showed significantly lower points in group of patients with NAS and SCHD combination compared to the group of patients with isolated SCHD (in total, by 8.76%; p <0.05).
Conclusion. Patients with metabolic syndrome in combination with stable coronary heart disease (SCHD) had a statistically significantly lower level of quality of life according to the evaluation by both SF-36 nonspecific questionnaire and the SAQ specific questionnaire comparing to group of patients with isolated SCAD.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Korylchuk NІ. Sposib zhyttia yak osnova metabolichnoho syndromu: pohliad na nashi realii [Lifestyle as the basis of metabolic syndrome: a look at our realities]. Visnyk sotsialnoi hihiieny ta orhanizatsii okhorony zdorovia Ukrainy [Bulletin of social hygiene and health care organization of Ukraine]. 2019;3:114-123 (in Ukranian).
Trybrat ТА. Metabolichnyi syndrom I zdorovyi obraz zhyttia. [Metabolic syndrome and healthy lifestyle]. Visnyk problem biolohii i medytsyny [Bulletin of problems of biology and medicine]. 2017;2 (136):30-33.
Babinets LS, Меlnyk NA, Shevchenko NO, Migenko BO, Zaets TA. Kallikrein-kinin system disbalance in chronic pancreatis in combination with metabolic syndrome. Wiadomosci lekarskie. 2019;72(11 cz 1):2113-2126.
The metabolic syndrome: Validity and utility of clinical defenitions for cardiovascular disease and diabetes risk prediction. Maturitas. 2010;65(2):117-121.
Babinets LS, Melnyk NA, Shevchenko NO et al. Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome. Wiadomosci lekarskie. 2018;71(2 cz 1):337-340.
Bondarenko ОО, Sorochka МІ. Metabolichnyi syndrom: dovhyi shliakh evoliutsii – vid povnoho zaperechennia do vsesvitnoho vyznannia problemy [Metabolic syndrome: a long way of evolution – from complete denial to worldwide recognition of the problem]. Zdobutky klinichnoi i eksperymentalnoi medytsyny [Achievements of clinical and experimental medicine]. 2018;3:13-19.
Tsunoda F, Asztalos IB, Horvath KV et al. Fenofibrate, HDL, and cardiovascular disease in type-2 diabetes: The DAIS trial. Atherosclerosis. 2016; 247:35-39.
Vishram JK, Borglykke A, Andreasen A et al. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. 2014. PLoS ONE; 9(9):e107294.
Palychata МV, Babinets LS, Proniuk ОV. Quality of life patients with chronic pancreatitis and related anemia. Zdobutky klinichnoi i eksperymentalnoi medytsyny [Achievements of clinical and experimental medicine]. 2017;2:113-114.
Limon VM, Lee M, Gonzalez B, Choh AC, Czerwinski SA. The impact of metabolic syndrome on mental health-related quality of life and depressive symptoms. Quality of Life Research. 2020;29(8):2063-2072.
Chrastina J, Bednářová D, Ludíková L et al. Quality of life in patients with chronic pancreatitis – Possibilities of measurement of the phenomenon in research. Kontakt. 2015;17:89-95.
Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation. 2005;112:e285-e290.
ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Practice Guideline. European Heart Journal. 2020;41(3):407-477.
Nakaz Ministerstva okhorony zdorovia Ukrainy «Unifikovanyi klinichnyi protocol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy stabilna ishemichna khvoroba sertsia» № 152 vid 02.03.2016 r. [Order of the Ministry of Health of Ukraine «Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care for stable coronary heart disease» № 152 of 02.03.2016].
Spertus JA, Winder JA, Dewhurst TA, Deyo R. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. Am Coll Cardiol. 1995;25(2):333-341.
